These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 18566593

  • 1. Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation.
    Fogari R, Derosa G, Ferrari I, Corradi L, Zoppi A, Lazzari P, Santoro T, Preti P, Mugellini A.
    Am J Hypertens; 2008 Sep; 21(9):1034-9. PubMed ID: 18566593
    [Abstract] [Full Text] [Related]

  • 2. Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus.
    Fogari R, Zoppi A, Mugellini A, Corradi L, Lazzari P, Preti P, Derosa G.
    J Cardiovasc Pharmacol; 2008 Mar; 51(3):217-22. PubMed ID: 18356684
    [Abstract] [Full Text] [Related]

  • 3. Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation.
    Fogari R, Mugellini A, Zoppi A, Preti P, Destro M, Lazzari P, Derosa G.
    J Cardiovasc Pharmacol Ther; 2012 Mar; 17(1):34-43. PubMed ID: 21335482
    [Abstract] [Full Text] [Related]

  • 4. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
    Palatini P, Dorigatti F, Mugellini A, Spagnuolo V, Varì N, Ferrara R, Bertocchi F.
    Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
    [Abstract] [Full Text] [Related]

  • 5. Differential time effect profiles of amlodipine, as compared to valsartan, revealed by ambulatory blood pressure monitoring, self blood pressure measurements and dose omission protocol.
    Radauceanu A, Boivin JM, Bernaud C, Fay R, Zannad F, CIC General Practitioners Investigators' Group.
    Fundam Clin Pharmacol; 2004 Aug; 18(4):483-91. PubMed ID: 15312156
    [Abstract] [Full Text] [Related]

  • 6. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
    Miranda RD, Mion D, Rocha JC, Kohlmann O, Gomes MA, Saraiva JF, Amodeo C, Filho BL.
    Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial.
    Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua TA, VALUE Trial Group.
    J Hypertens; 2008 Mar; 26(3):403-11. PubMed ID: 18300848
    [Abstract] [Full Text] [Related]

  • 9. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients.
    Fogari R, Zoppi A, Derosa G, Mugellini A, Lazzari P, Rinaldi A, Fogari E, Preti P.
    J Hum Hypertens; 2007 Mar; 21(3):220-4. PubMed ID: 17215848
    [Abstract] [Full Text] [Related]

  • 10. Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence.
    Disertori M, Latini R, Maggioni AP, Delise P, Di Pasquale G, Franzosi MG, Staszewsky L, Tognoni G, GISSI-AF Investigators.
    J Cardiovasc Med (Hagerstown); 2006 Jan; 7(1):29-38. PubMed ID: 16645357
    [Abstract] [Full Text] [Related]

  • 11. Valsartan for prevention of recurrent atrial fibrillation.
    GISSI-AF Investigators, Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, Lucci D, Di Pasquale G, Tognoni G.
    N Engl J Med; 2009 Apr 16; 360(16):1606-17. PubMed ID: 19369667
    [Abstract] [Full Text] [Related]

  • 12. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial.
    Zanchetti A, Julius S, Kjeldsen S, McInnes GT, Hua T, Weber M, Laragh JH, Plat F, Battegay E, Calvo-Vargas C, Cieśliński A, Degaute JP, Holwerda NJ, Kobalava J, Pedersen OL, Rudyatmoko FP, Siamopoulos KC, Störset O.
    J Hypertens; 2006 Nov 16; 24(11):2163-8. PubMed ID: 17053536
    [Abstract] [Full Text] [Related]

  • 13. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
    Miyajima K, Minatoguchi S, Ito Y, Hukunishi M, Matsuno Y, Kakami M, Kawasaki M, Nishigaki K, Takemura G, Fujiwara H.
    Hypertens Res; 2007 Apr 16; 30(4):307-13. PubMed ID: 17541209
    [Abstract] [Full Text] [Related]

  • 14. Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study.
    Lacourcière Y, Wright JT, Samuel R, Zappe D, Purkayastha D, Black HR, EVALUATE study.
    Blood Press Monit; 2009 Jun 16; 14(3):112-20. PubMed ID: 19384192
    [Abstract] [Full Text] [Related]

  • 15. Clinical predictors of atrial fibrillation recurrence in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial.
    Disertori M, Lombardi F, Barlera S, Latini R, Maggioni AP, Zeni P, Di Pasquale G, Cosmi F, Franzosi MG, GISSI-AF Investigators.
    Am Heart J; 2010 May 16; 159(5):857-63. PubMed ID: 20435196
    [Abstract] [Full Text] [Related]

  • 16. Comparing antihypertensive effect and plasma ciclosporin concentration between amlodipine and valsartan regimens in hypertensive renal transplant patients receiving ciclosporin therapy.
    Cai J, Huang Z, Yang G, Cheng K, Ye Q, Ming Y, Zuo X, Zhou P, Yuan H.
    Am J Cardiovasc Drugs; 2011 Dec 01; 11(6):401-9. PubMed ID: 22149319
    [Abstract] [Full Text] [Related]

  • 17. Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients.
    Belluzzi F, Sernesi L, Preti P, Salinaro F, Fonte ML, Perlini S.
    J Am Coll Cardiol; 2009 Jan 06; 53(1):24-9. PubMed ID: 19118720
    [Abstract] [Full Text] [Related]

  • 18. Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial.
    Kjeldsen SE, McInnes GT, Mancia G, Hua TA, Julius S, Weber MA, Coca A, Girerd X, Jamerson K, Larochelle P, Macdonald T, Schmieder RE, Anthony Schork M, Viskoper R, Widimsky J, Zanchetti A.
    Blood Press; 2008 Jan 06; 17(3):170-7. PubMed ID: 18608200
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness of valsartan for treatment of hypertension: patient profiling and hierarchical modeling of determinants and outcomes (the PREVIEW study).
    Van der Niepen P, Woestenburg A, Brié H, Vancayzeele S, MacDonald K, Denhaerynck K, Lee C, Hermans C, Abraham I.
    Ann Pharmacother; 2009 May 06; 43(5):849-61. PubMed ID: 19351876
    [Abstract] [Full Text] [Related]

  • 20. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial.
    Kjeldsen SE, Julius S, Mancia G, McInnes GT, Hua T, Weber MA, Coca A, Ekman S, Girerd X, Jamerson K, Larochelle P, MacDonald TM, Schmieder RE, Schork MA, Stolt P, Viskoper R, Widimský J, Zanchetti A, VALUE Trial Investigators.
    J Hypertens; 2006 Jul 06; 24(7):1405-12. PubMed ID: 16794491
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.